Switch theme
Sign up to access all valuation multiples
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
2002
33
LTM Revenue $0.5M
Last FY EBITDA -$48.2M
$131M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cardiff Oncology has a last 12-month revenue (LTM) of $0.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cardiff Oncology achieved revenue of $0.7M and an EBITDA of -$48.2M.
Cardiff Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cardiff Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | XXX | $0.7M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$48.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -7064% | XXX | XXX | XXX |
| EBIT | -$54.1M | XXX | -$48.7M | XXX | XXX | XXX |
| EBIT Margin | -10088% | XXX | -7123% | XXX | XXX | XXX |
| Net Profit | -$51.2M | XXX | -$45.4M | XXX | XXX | XXX |
| Net Margin | -9538% | XXX | -6652% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Cardiff Oncology's stock price is $3.
Cardiff Oncology has current market cap of $210M, and EV of $131M.
See Cardiff Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $131M | $210M | XXX | XXX | XXX | XXX | $-0.88 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Cardiff Oncology has market cap of $210M and EV of $131M.
Cardiff Oncology's trades at 192.3x EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate Cardiff Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cardiff Oncology has a P/E ratio of -4.1x.
See valuation multiples for Cardiff Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $210M | XXX | $210M | XXX | XXX | XXX |
| EV (current) | $131M | XXX | $131M | XXX | XXX | XXX |
| EV/Revenue | 244.8x | XXX | 192.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | -2.4x | XXX | -2.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.1x | XXX | -4.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCardiff Oncology's last 12 month revenue growth is -30%
Cardiff Oncology's revenue per employee in the last FY averaged $21K, while opex per employee averaged $1.5M for the same period.
Cardiff Oncology's rule of 40 is -9254% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cardiff Oncology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cardiff Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -30% | XXX | -27% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -7064% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -9254% | XXX | -7094% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $21K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5396% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 7223% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cardiff Oncology acquired XXX companies to date.
Last acquisition by Cardiff Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Cardiff Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cardiff Oncology founded? | Cardiff Oncology was founded in 2002. |
| Where is Cardiff Oncology headquartered? | Cardiff Oncology is headquartered in United States of America. |
| How many employees does Cardiff Oncology have? | As of today, Cardiff Oncology has 33 employees. |
| Who is the CEO of Cardiff Oncology? | Cardiff Oncology's CEO is Dr. Mark Erlander, PhD. |
| Is Cardiff Oncology publicy listed? | Yes, Cardiff Oncology is a public company listed on NAS. |
| What is the stock symbol of Cardiff Oncology? | Cardiff Oncology trades under CRDF ticker. |
| When did Cardiff Oncology go public? | Cardiff Oncology went public in 1997. |
| Who are competitors of Cardiff Oncology? | Similar companies to Cardiff Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cardiff Oncology? | Cardiff Oncology's current market cap is $210M |
| What is the current revenue of Cardiff Oncology? | Cardiff Oncology's last 12 months revenue is $0.5M. |
| What is the current revenue growth of Cardiff Oncology? | Cardiff Oncology revenue growth (NTM/LTM) is -30%. |
| What is the current EV/Revenue multiple of Cardiff Oncology? | Current revenue multiple of Cardiff Oncology is 244.8x. |
| Is Cardiff Oncology profitable? | Yes, Cardiff Oncology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
